胺碘酮与厄贝沙坦联用对病态窦房结综合征人工心脏起搏后的疗效

目的观察厄贝沙坦和胺碘酮联用对病态窦房结综合征(病窦综合征)并阵发性心房颤动(房颤)双腔起搏(DDD)起搏后房颤发生率的影响。方法选取病窦综合征并阵发性房颤患者60例,DDD起搏后随机分为胺碘酮组(30例)和厄贝沙坦+胺碘酮组(30例),胺碘酮组治疗方案:DDD起搏后,给予胺碘酮0.2 g,口服1次/d;厄贝沙坦+胺碘酮组在上述方案基础上加厄贝沙坦75~150 mg/d,疗程观察18个月。结果与胺碘酮组比较,厄贝沙坦+胺碘酮组房颤的发生率明显降低(P<0.05),且厄贝沙坦+胺碘酮组窦性心律维持率高于胺碘酮组。结论厄贝沙坦联合胺碘酮对植入DDD型起搏器患者心房颤动的发生有明显的协同抑制作用。

Effect of amiodarone combined with irbesartan on incidence of sick sinus syndrom with paroxysmal atrial fibrillation after DDD pacemaker implantation

Objective To observe effect of amiodarone combined with irbesartan on incidence of sick sinus syndrom with paroxysmal atrial fibrillation after DDD pacemaker implantation. Methods 60 cases of SSS patients with paroxysmal atrial fibrillation were randomized to group A （30 cases） treated with amiodarone or group B （30 cases ） treated with amiodarone plus irbesartan. Results During the 18 month follow - up,the incidence of artrial fibrillation in group was lower significantly than that in group A（ P 〈0. 05 ） ;Sinus rhythm was maintained in 66.6% patients in group A and in 80% patients in group B, which had significant difference （ P 〈 0. 05 ）. Conclusion Irbesartan may be favorable in reducing the incidence of Sick Sinus Syndrom with Atrial Fibrillation after DDD Pacemaker implantation.